CN104351761B - 一种超高压射流破壁灵芝孢子粉及口服液工艺装置 - Google Patents
一种超高压射流破壁灵芝孢子粉及口服液工艺装置 Download PDFInfo
- Publication number
- CN104351761B CN104351761B CN201410548543.7A CN201410548543A CN104351761B CN 104351761 B CN104351761 B CN 104351761B CN 201410548543 A CN201410548543 A CN 201410548543A CN 104351761 B CN104351761 B CN 104351761B
- Authority
- CN
- China
- Prior art keywords
- ganoderma
- selenium
- spore powder
- pressure
- rich
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000222336 Ganoderma Species 0.000 title claims abstract description 117
- 239000000843 powder Substances 0.000 title claims abstract description 60
- 238000000034 method Methods 0.000 title claims abstract description 54
- 239000007788 liquid Substances 0.000 title claims abstract description 47
- 230000001413 cellular effect Effects 0.000 title claims abstract description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 230000008569 process Effects 0.000 title abstract description 19
- 239000011669 selenium Substances 0.000 claims abstract description 37
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 36
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 36
- 239000007921 spray Substances 0.000 claims abstract description 30
- 230000035939 shock Effects 0.000 claims abstract description 23
- 244000287839 Vaccinium bracteatum Species 0.000 claims abstract description 20
- 235000005480 Vaccinium bracteatum Nutrition 0.000 claims abstract description 19
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 15
- 240000006794 Volvariella volvacea Species 0.000 claims abstract description 14
- 235000004501 Volvariella volvacea Nutrition 0.000 claims abstract description 14
- 244000309464 bull Species 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 241000241413 Propolis Species 0.000 claims abstract description 11
- 229940069949 propolis Drugs 0.000 claims abstract description 11
- 244000017020 Ipomoea batatas Species 0.000 claims abstract description 10
- 235000002678 Ipomoea batatas Nutrition 0.000 claims abstract description 10
- 238000001914 filtration Methods 0.000 claims abstract description 7
- 238000005516 engineering process Methods 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000010009 beating Methods 0.000 claims description 6
- 238000003860 storage Methods 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 230000000087 stabilizing effect Effects 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000011344 liquid material Substances 0.000 claims description 3
- 239000006166 lysate Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 240000008397 Ganoderma lucidum Species 0.000 abstract description 19
- 235000001637 Ganoderma lucidum Nutrition 0.000 abstract description 19
- 238000013461 design Methods 0.000 abstract description 16
- 230000008901 benefit Effects 0.000 abstract description 9
- 238000004880 explosion Methods 0.000 abstract description 9
- 230000026676 system process Effects 0.000 abstract description 4
- 241000411851 herbal medicine Species 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 23
- 238000009527 percussion Methods 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000005728 strengthening Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 238000005192 partition Methods 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000007599 discharging Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011343 solid material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229920002101 Chitin Polymers 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229930014669 anthocyanidin Natural products 0.000 description 3
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 3
- 235000008758 anthocyanidins Nutrition 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 208000007443 Neurasthenia Diseases 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000000956 alloy Substances 0.000 description 2
- 229910045601 alloy Inorganic materials 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000005422 blasting Methods 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 239000002360 explosive Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 239000010437 gem Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 238000004537 pulping Methods 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 238000005245 sintering Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000005514 two-phase flow Effects 0.000 description 2
- 238000003466 welding Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 235000007926 Craterellus fallax Nutrition 0.000 description 1
- 240000007175 Datura inoxia Species 0.000 description 1
- 241000170036 Endosporium Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 241000371997 Eriocheir sinensis Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000282342 Martes americana Species 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920001231 Polysaccharide peptide Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 231100000739 chronic poisoning Toxicity 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- -1 phenol glycoside Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108010022457 polysaccharide peptide Proteins 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/30—Physical treatment, e.g. electrical or magnetic means, wave energy or irradiation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/10—General methods of cooking foods, e.g. by roasting or frying
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/10—General methods of cooking foods, e.g. by roasting or frying
- A23L5/17—General methods of cooking foods, e.g. by roasting or frying in a gaseous atmosphere with forced air or gas circulation, in vacuum or under pressure
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/40—Shaping or working of foodstuffs characterised by the products free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
本发明创新设计具有不同于现有工艺的特点,是由气、液、固三相流在500Mpa以上的液态压力下爆破配合超音速射流撞击灵芝孢子粉提高破壁率,具体说是一种超高压射流破壁灵芝孢子粉及口服液工艺装置,属于生物工程、中草药细胞爆破提取技术创新领域,是提高灵芝孢子粉破壁率的专用工艺及装置,工艺由灵芝孢子粉80%、丰城草菇5%、蜂胶5%、富硒南烛5%、富硒紫薯汁5%及纯净水30~45%组成,经超高压蓄能器、超音速射流撞击破壁、过滤浓缩,装置由超高压发生器、蓄能器、高压射流器、喷嘴、双向撞击靶、混凝器、空气压缩机、系统控制电脑等主要部件组成,通过管路连接传感器、压力指示器等附件的系统工艺装置。
Description
技术领域
本实用创新设计具有不同于现有工艺的特点,是由气、液、固三相流在500Mpa 以上的液态压力下爆破、超音速射流撞击灵芝孢子粉提高破壁率,具体说是一种超高压射流破壁灵芝孢子粉及口服液工艺装置,属于生物工程、中草药细胞爆破提取技术创新领域。
背景技术
目前国外多用高压气流法植物细胞破壁,由于灵芝孢子粉部分破壁后孢子粉中的多糖类物质把其他孢子粉粘在一起,无法继续操作下去,也有采用酶法破壁,破壁率最高只能够达到42 %, 及超声波破壁、低温冷冻破壁等,这些方法普遍存在成本高、破壁率相对较低等缺点,撞击流粉碎技术已经用于超细炸药、超细涂料的制备,超高压超临界撞击流粉碎试验系统,制备破壁灵芝孢子只取得了较为满意的效果 。
为了进一步提高破壁率,有必要分析灵芝孢子在超高压撞击流下的破壁机理,从灵芝孢子粉破壁的过程出发,结合灵芝孢子粉的结构,分析了孢子在原料罐中及刚出喷嘴时孢壁的受力分析、超高压超临界流体气爆时孢壁的受力分析、以及孢子撞击靶板时的受力分析,从而研究其破壁机理。
一、超高压撞击流技术制备破壁灵芝孢子 撞击流( Impinging St reams 简称IS) 的概念于20 世纪60 年代初由Elpe rin 首先提出并进行试验,撞击流方法采用特殊的流动结构,即两股很靠近的等量气―固两相流沿同轴相向流动、并在中点处撞击,其基本原理是使混有固体物料的高压流体( 通常大于200MPa) 通过喷嘴加速,形成高速射流带动其中的固体颗粒作高速运动,然后与靶板( 超硬材料, 如金刚石或宝石) 或相反方向的另一股射流形成高速强烈撞击,射流碰撞的结果导致产生一个狭窄的高压、高速湍流区,在此区域内相间或颗粒之间的碰撞、互磨产生的挤压力和剪切力使流体中的固体物料被细化只是(气固二相流)。
二、根据撞击流技术的原理:将含有灵芝孢子的超临界二氧化碳加压到200MPa以上的超高压,通过0. 1mm 的喷嘴后喷射到硬质合金的靶子上,通过旋风分离器收集产物,扫描电镜观察,孢壁结构被破坏,采用血球计数法统计, 在加载压力300MPa , 温度130 ℃,撞击靶距10mm 及保压时间1h 的工艺条件下,灵芝孢子的破壁率为88. 48 %。
灵芝孢子粉本身富含硒元素,灵芝孢子粉是灵芝发育后期弹射释放出来的种子,生物学上称担孢子,孢子内含有比灵芝更为丰富的多糖肽、腺嘌呤核苷、蛋白质、酶类及硒元素等特殊成份,在自然界中,由于风吹雨淋,灵芝无法积累孢子,收集孢子粉非常困难,在电子显微镜下观察,灵芝孢子粉成熟度与营养条件有关,段木栽培出的灵芝孢子粉比袋料栽培的大、饱满,有效成分含量也更高,随着科学技术的发展,对灵芝孢子粉的破壁技术有了很大提高,其保健功效也为世人瞩目。
参考文件:中国食用菌第一期第20 卷:灵芝孢子粉破壁工艺与装备,介绍了以30-70Mpa 高压均质及超声波、酶法破壁,其得率及低只是在32% 的破壁率,量产工艺成本高。
参考文件:
一种灵芝孢子粉破壁机授权专利号:2011201613423,所述的轧棍再紧密相邻,也难满足6 微米左右的灵芝孢子的粒径完全破壁,尤其灵芝孢子粒径为长圆形、破壁后油性、硬度6 级以上,轧棍紧密相邻工艺复杂、精度要求高,在强行转动时耗能大、工艺成本高。
参考文件:
灵芝孢子粉破壁方法专利公布号:2010101811513,所述工艺冰冻加烘烤、原理为热胀冷缩,光用这单一方法不可能将6 级以上硬度的灵芝孢子破壁。
参考文件:
灵芝孢子粉的湿法破壁方法授权号:2009100307023 ;
一种灵芝孢子破壁方法专利公布号:2012100847428 ;
一种灵芝孢子油的制备方法专利公布号:201410164720.1 ;
一种全效灵芝保健品的制作方法专利公布号:201210434942.1 ;
一种高生物活性灵芝孢子油及其超临界制备方法专利公布号:2012105667474 ;
分析以上专利陈述内容都属于在用工艺中的变革,缺少真正创新发明的实际效果,基本上是提升了理论上的结果,也就不一一陈述了。
本创新设计的一种超高压射流破壁灵芝孢子粉及口服液工艺装置,具有不同于现有工艺的特点是由:气、液、固三相流在500Mpa 以上的液态压力下爆破撞击灵芝孢子粉破壁,过滤后成为灵芝孢子破壁口服液,由于在破壁过程中有效成分在液态不被氧化变质,采用南烛、紫薯植物作为抗氧化添加剂,克服了现用工艺下造成的易氧化的缺陷,破壁灵芝孢子口服液中有效成分被保护,就不易氧化变质货架期长,十年泰山许仙草,喜羊羊、灰太狼,灵芝苞子、蓝梅话凄凉;纵使相逢应不识,白素珍、美猴王,老夫聊发少年狂,治肾亏、不含糖,锦帽貂裘,壮阳用奇强;为报倾城上九天,五百年、破壁堂,夜观天象量子楼,学外语、超高压,相顾无言,一克便健康;欲问破壁谁家强?机场雷、硕放乡。
发明内容
鉴于上述缺点分析:用高压气流法破壁灵芝孢子粉部分破壁后,孢子粉中的多糖类物质把其他孢子粉粘在一起,气流法已经无法继续撞击、破壁率始终超不过50%,也有采用酶法破壁,破壁率最高只能够达到42 %,采用超声波破壁、低温冷冻破壁等方法又普遍存在成本高、破壁率相对较低等缺点,撞击流粉碎技术已经用于超细炸药、超细涂料的制备,超高压超临界撞击流粉碎试验系统,制备破壁灵芝孢子只取得了较为满意的效果 。
为了进一步提高破壁率,有必要分析灵芝孢子在超高压撞击流下的破壁机理,从灵芝孢子粉破壁的过程出发, 结合灵芝孢子粉的结构,分析了孢子在原料罐中及刚出喷嘴时孢壁的受力分析、超高压超临界流体气爆时孢壁的受力分析、以及孢子撞击靶板时的受力分析,从而研究其破壁机理。 一、超高压撞击流技术制备破壁灵芝孢子:撞击流(Impinging St reams 简称IS) 的概念于20 世纪60 年代初由Elpe rin 首先提出并进行试验,撞击流方法采用特殊的流动结构,即两股很靠近的等量气―固两相流沿同轴相向流动、并在中点处撞击,其基本原理是使混有固体物料的高压流体( 通常大于200MPa) 通过喷嘴加速,形成高速射流带动其中的固体颗粒作高速运动,然后与靶板( 超硬材料, 如金刚石或宝石) 或相反方向的另一股射流形成高速强烈撞击,射流碰撞的结果导致产生一个狭窄的高压、高速湍流区,在此区域内相间或颗粒之间的碰撞、互磨产生的挤压力和剪切力使流体中的固体物料被细化。
二、根据撞击流技术的原理:将含有灵芝孢子的超临界二氧化碳加压到200MPa以上的超高压,通过0. 1mm 的喷嘴后喷射到硬质合金的靶子上,通过旋风分离器收集产物,扫描电镜观察,孢壁结构被破坏,采用血球计数法统计,在加载压力300MPa ,温度130℃ , 撞击靶距10mm 及保压时间1h 的工艺条件下,灵芝孢子的破壁率为88. 48 %(气固二相流)。
根据上述原理,本创新设计的一种超高压射流灵芝孢子粉及破壁工艺装置,具有不同于现有工艺的特点是:气、液、固三相流在500Mpa 以上的液态压力下爆破撞击灵芝孢子粉破壁,破壁率高、灵芝多糖肽纯度高质量好,灵芝孢子粉有一种油腥味而无异味,因含有25% 的灵芝孢子油,颜色为深棕色,用开水冲,表面有油星(孢子油);如果是未破壁灵芝孢子粉为浅黄色,色泽浅的破壁灵芝孢子粉是由于破壁率低或灵芝孢子油含量低,或者采粉工艺不当有杂质产生异味,灵芝孢子粉的生长环境、采集条件、破壁工艺是决定灵芝孢子粉质量破壁率的关键,为此设计的工艺系统装置特点在于(气、液、固三相流)。
以下着重分析下灵芝孢子在超高压撞击流下的破壁原理,这一项研究主要目的是为了进一步提高灵芝孢子的破壁率,使用超高压与超临界撞击流二方法结合,制备的破壁灵芝孢子破壁率,从灵芝孢子粉破壁的过程出发,在灵芝孢子粉的结构上,分析了孢子在原料罐中及刚出喷嘴时孢壁的受力分析,超高压超临界流体撞击爆破孢壁时的受力分析,以及孢子撞击靶板时的受力分析。
在扫描电镜下可见灵芝孢子呈卵圆形,顶端平截或钝圆锥形,孢子大小约为5.6μm ×8. 5μm 的双层孢壁,两层间有小棘,Coleman(1927) 研究灵芝孢壁构造时曾指出:几丁质内孢壁的存在使得孢子难以萌发,结构复杂、坚硬且耐酸碱的孢壁影响了孢子内含物的释放,限制了对其生物活性成分的提取,生物利用率低,曾提取灵芝孢壁成分几丁质的红外光谱特征;与对照样品蟹壳中的几丁质基本一样,无机元素构成以Si (19. 01 %) 、Ca (24 . 31 %) 为主,硅和钙参入几丁质使得孢壁更加结实坚硬,研究结果表明;灵芝孢子破壁后化学成分更易提取,有利于人体有效地吸收有效成分,因此:进行破壁处理是必要的。
从上世纪70 年代开始,我国的医学工作者就开始致力于揭开灵芝的神秘面纱,药理研究表明,灵芝自身富集硒,主要含赖氨酸、亮氨酸等15 种氨基酸和甜菜碱等4 种生物碱以及钠、钾、钙、铜、锌等13 种无机元素,此外,有机硒富集、蛋白质、灵芝多糖肽的含量也十分丰富,灵芝能增强神经中枢神经系统功能,强心、改善冠状动脉血液循环,增加心肌缺血氧供应,降压、降脂、护肝,提高机体免疫功能,促进周围血中白细胞增加,并有抗过敏、止咳、祛痰及抗辐射的作用。
临床验证,灵芝的应用范围非常广泛,就中医辩证看,灵芝扶正固本,增强免疫功能,提高机体抵抗力,灵芝可入五脏气补全身,心、肺、肝、脾、肾脏虚弱均可服之,灵芝所治病种涉及呼吸、循环、消化、神经、内分泌及运动等各个系统;涵盖内、外、妇、儿、五官各科疾病,具体而言,灵芝有八点好处:
1 保肝解毒:灵芝能促进肝脏对药物,毒物的代谢,有效的改善肝功能,对治疗各种慢性肝炎,慢性中毒有确切疗效. ;
2 抗衰老:灵芝含有的多糖,多肽有促进和调整免疫功能;调节代谢平衡;促进核酸和蛋白质的合成;灵芝多糖能显著促进细胞核内DNA 合成;明显的延缓细胞衰老,养颜青春,延年益寿;
3. 预防心血管疾病: 灵芝可有效的扩张冠状动脉,增加冠脉血流量, 改善心肌微循环,增强心肌氧和能量的供给,灵芝可明显的降低胆固醇、脂蛋白和甘油三脂;
4 抗神经衰弱:灵芝对中枢神经系统有较强的调节抑制作用,具有镇静安神的功效及对神经衰弱、失眠患者有显著的疗效;
5 治疗高血压:灵芝可使血压降低并具有延长和稳定其它降压药物的效果;
6 治疗糖尿病:灵芝中的水溶性多糖可以减轻非胰岛素依赖型糖尿病的发病程度;服用灵芝后可以取代胰岛素抑制脂肪酸的释出,可以改善血糖, 尿糖的症状;
7 治疗慢性气管炎:灵芝有显著的镇静、祛痰、平喘功效、有显著的效果,并可有效地防止反复感冒;
8 美 容:灵芝能调节皮肤水分恢复皮肤弹性,使皮肤细腻湿润,并可以抑制皮肤中的黑色素的形成和沉淀,具有养颜护肤美容的功效。
灵芝有滋补强壮、延年益寿及松弛身心等益处,关于灵芝的疗效,最早记载于《神农本草经》,书中将灵芝列为“上上药”,所谓“上药”就是最珍贵的药物,完全没有副作用,长期服用能改善体质;此外明代大医学家李时珍《本草纲目》中对灵芝的疗效也都有记载,而后代的中药典籍基本上都记载了灵芝的疗效,《本草纲目》中对灵芝的描述是“灵芝性平、味苦、无毒,主胸中结、益心气、补中,增智健脑强记忆,久服轻身不老,延年益寿”,灵芝作为一种珍贵的中草药物,自古至今以来都是人们治病养身的上上之选,灵芝的研究在古代就已经开始一直到现在,灵芝是一种既可以入药,也可以当做保健材料来处理,中医认为,野生灵芝性甘、性平,可入心经、肺经、肝经和肾经,具有补气安神、止咳定喘的功效,现代医学研究发现,野生灵芝中含有天然的有机锗、灵芝多糖、灵芝酸、灵芝孢子内脂、腺苷、灵芝碱、灵芝尿嘧啶、油酸和灵芝纤维素等多种对人体有益的成分,灵芝扶正固本,增强免疫功能,提高机体抵抗力的巨大作用,它不同于一般药物对某种疾病而起治疗作用,亦不同于一般营养保健食品只对某一方面营养素的不足进行补充和强化,而是在整体上双向调节人体机能平衡,调动机体内部活力,调节人体新陈代谢机能,提高自身免疫能力,促使全部的内脏或器官机能正常化。
灵芝的功效和作用要得到最优的发挥,其调理治疗疾病要达到理想的效果就必须要对灵芝经过加工处理,市场上我们所能见到的灵芝产品,如灵芝孢子粉、灵芝孢子油,其有效成分最大限度只能提取达50%,在吸收和药效上都不能达到理想的效果,甚至还会伤害患者肠胃,只有将灵芝进行高纯度萃取,制成高浓缩型破壁灵芝孢子粉、或者液态灵芝口服液才能保存其最大有效成分,相对于其他灵芝产品,灵芝口服液的优势是更容易充分吸收,能将灵芝的药效发挥到最大。
有益效果
本创新设计具有不同于现有工艺的特点,是由气、液、固三相流在500Mpa 以上的液态压力下爆破、超音速射流撞击灵芝孢子粉提高破壁率,具有属于生物工程、中草药细胞爆破提取技术创新领域特点,是提高灵芝孢子粉破壁率的专用工艺及装置,工艺由灵芝孢子粉80%、丰城草菇5%、蜂胶5%、富硒南烛5%、富硒紫薯汁5% 及纯净水30 ~ 45% 组成,经超高压蓄能器、超音速射流撞击破壁、过滤浓缩,装置由超高压发生器、蓄能器、高压射流器、喷嘴、双向撞击靶、混凝器、空气压缩机、系统控制电脑等主要部件组成,通过管路连接传感器、压力指示器等附件的系统工艺装置,与现用工艺比:具有耗能低、运转成本低、破壁率高的特点。
附图说明
附图1 是:装置系统回路图;
附图2 是:高压射流器剖面图;
其中:超高压发生器=(A),高压射流器=(B),蓄能器=(C),混凝器=(D),空气压缩机=(E),系统控制电脑=(F),加速管=b1,喷嘴=b2,隔断档板=b3,双向撞击靶=b4,出料口=b5,进气管=b6,虹吸管=b7。
技术方案
一种超高压射流破壁灵芝孢子粉及口服液工艺装置,其特征是:口服液工艺由灵芝孢子粉80%、丰城草菇5%、蜂胶5%、富硒南烛5%、富硒紫薯汁5% 及纯净水30 ~ 45% 组成,经超高压蓄能器、超音速射流撞击破壁、过滤浓缩,装置由超高压发生器、蓄能器、高压射流器、喷嘴、双向撞击靶、混凝器、空气压缩机、系统控制电脑等主要部件组成,通过管路连接传感器、压力指示器等附件的系统工艺。
先将丰城草菇(干)5% 用适量的纯净水浸泡后打浆过滤,再将5% 富硒南烛、5% 富硒
紫薯清洗后加适量的纯净水打浆过滤,再把丰城草菇过滤汁与富硒南烛、富硒紫薯汁混合后备用,二是:用适量的纯净水与蜂胶5% 放在混凝器中溶解备用,再在30 ~ 45% 的纯净水中加入灵芝孢子粉70% 混合后为G 液注入蓄能器,启动超高压发生器,由程序指示器打开管路控制阀,超高压发生器为蓄能器增压。
再将丰城草菇5%、富硒南烛5%、富硒紫薯汁5% 的过滤液与5% 蜂胶溶解液一起混合后,进超高压容器以450Mpa 超高压压力破壁、杀菌5min 取出为H 液备用,然后将G 液与H液经混凝器充分混合后注入超高压反应釜,采用500Mpa 压力稳压10 ~ 15min 释压后进入存储罐,在高压射流器两侧进料口的虹吸作用下液料从喷嘴中喷出,同轴线对向喷射在撞击靶上破壁。
所述的高压射流器、喷嘴、双向撞击靶的专用设计,高压射流器两侧中心固定安装喷嘴,高压射流器箱体中间有隔断档板,双向撞击靶固定安装在隔断的中心孔上,双向撞击靶材质是由二氧化硅粉85%、碳酸钙粉15% 的混合物,经超高压成型、二次烧结而成。
所述的超高压发生器为单缸双作用隔腔式,由于灵芝孢子粉、口服液的食用卫生级要求高,柱塞采用二氧化硅粉、碳酸钙粉的混合物经超高压成型后烧结而成,今后本发明人雷鉴源将另行专利申请不再详述,蓄能器为二层不同材质热套,高压射流器、喷嘴、双向撞击靶为本装置的专用设计(附图2),混凝器、空气压缩机为市场购买的常规配套件。
所述的富硒南烛是野生植物南烛树叶打成浆的过滤汁,含有槲皮素及酚甙和蓝黑色素以及富含Fe 、B、Mn、Zn 等微量元素,其嫩叶是重要的药材,抗溃疡、抗炎症、抗衰老、抗氧化等多种药理活性,作为灵芝孢子粉破壁后防氧化的植物添加剂,其中含有花青素、β- 谷甾醇、熊果酸、蓝黑色素( 主要成分是槲皮素)、异荭草素、对羟基桂皮酸、内消旋肌醇、α- 亚麻酸、乌索酸、齐墩果酸、三十一烷及鞣质等。乌饭树叶具有促进视红素再合成、Vp 样机能、改善血液微循环。我们通过对乌饭树植物生理特性的研究,运用紫外光谱以及分光光度计等相关仪器对乌饭树叶的色素进行提取,分析,了解色素的特性以及所包含的抗氧化活性,并将这些研究成果运用于实践中,获得相应的经济效益。
所述的富硒紫薯汁是由种植的紫薯打成浆的过滤汁,作为灵芝孢子粉口服液的混凝剂,由于薯肉呈紫色至深紫色,除了具有普通红薯的营养成分外,还富含硒元素和花青素,紫薯为花青素的主要原料之一,通过超高压灭菌后的安全系数提高,灵芝孢子粉破壁后自身富含硒,加上南烛与紫薯具有的特性,使灵芝孢子口服液具有高含量多糖及硒富集,浓缩后的灵芝孢子多糖肽含量纯度更加高。
具体实施方式
下面按照附图1 进一步陈述:工艺过程: 由口服液工艺由灵芝孢子粉80%、丰城草菇5%、蜂胶5%、富硒南烛5%、富硒紫薯汁5% 及纯净水30 ~ 45% 组成,经超高压蓄能器、超音速射流撞击破壁、过滤浓缩,装置由超高压发生器(A),高压射流器(B),蓄能器(C),混凝器(D),空气压缩机(E),系统控制电脑(F),加速管b1,喷嘴b2,隔断档板b3,双向撞击靶b4,出料口b5,进气管b6,虹吸管b7 等主要部件组成,通过管路连接传感器、压力指示器等附件的系统工艺。
先将丰城草菇(干)5% 用适量的纯净水浸泡后打浆过滤,再将5% 富硒南烛、5% 富硒
紫薯清洗后加适量的纯净水打浆过滤,再把丰城草菇过滤汁与富硒南烛、富硒紫薯汁混合后备用,二是:用适量的纯净水与蜂胶5% 放在混凝器中溶解备用,再在30 ~ 45% 的纯净水中加入灵芝孢子粉70% 混合后为F 液注入蓄能器,启动超高压发生器,由程序指示器打开管路控制阀,超高压发生器为蓄能器增压。
再将丰城草菇5%、富硒南烛5%、富硒紫薯汁5% 的过滤液与5% 蜂胶溶解液一起混合后,进超高压容器以450Mpa 超高压压力破壁、杀菌5min 取出为G 液备用,然后将F 液与G 液经混凝器充分混合后注入超高压反应釜蓄能器(C),采用500Mpa 压力稳压10 ~ 15min释压后进入存储罐,在高压射流器两侧进料口的虹吸作用下液料从喷嘴中喷出,同轴线对向喷射在撞击靶上破壁。
所述的高压射流器、喷嘴、双向撞击靶的专用设计,高压射流器两侧中心固定安装喷嘴,高压射流器箱体中间有隔断档板,双向撞击靶固定安装在隔断的中心孔上,双向撞击靶材质是由二氧化硅粉85%、碳酸钙粉15% 的混合物,经超高压成型、二次烧结而成。
所述的超高压发生器为单缸双作用隔腔式,由于灵芝孢子粉、口服液的食用卫生级要求高,柱塞采用二氧化硅粉、碳酸钙粉的混合物经超高压成型后烧结而成,今后本发明人雷鉴源将另行专利申请不再详述,蓄能器为二层不同材质热套,高压射流器、喷嘴、双向撞击靶为本装置的专用设计,混凝器、空气压缩机为市场购买的常规配套件。
所述的超高压发生器A 管路链接蓄能器C,蓄能器C 一端有回路管链接高压射流器B 两侧的虹吸管b7,空气压缩机E 回路管链接高压射流器B 两侧的进气管b6,系统控制电脑(F) 线路链接混凝器D、空气压缩机E,由系统控制电脑F 线路链接超高压发生器A 的液压单元,链接安装按照(附图1)。
所述的高压射流器(B) 的中间段固定安装有隔断档板b3,在隔断档板b3 的中心部位嵌入双向撞击靶b4,两侧的进气管b6 上焊接虹吸管b7,进气管b6 段穿透高压射流器B两侧的中心,并露出可固定焊接的接口段,在段穿透高压射流器B 两侧进气管b6 的管中套入加速管b1,在穿入高压射流器B 两侧的中心进气管b6 的一端螺纹安装喷嘴b2,高压射流器B 的底部焊接漏斗形出料口b5,安装按照(附图2)。
当G、F 两液注入蓄能器(C)后,系统控制电脑(F) 启动超高压发生器(A)液压单元,程序指示器打开管路上的控制阀,超高压发生器(A)为蓄能器(C) 增压,按照程序设计要求的压力到后,稳压10 ~ 15min 时间后释放压力,同时启动空气压缩机(E),压缩机气流经回路管到进气管b6,在加速管b1 的作用产生至少一马赫以上的超音速气流作用在虹吸管b7 上,将蓄能器(C)中的F、G 混合液吸出,以至少超过一马赫的超音速从喷嘴b2 中喷射撞击在双向撞击靶b4 上,实现提高灵芝孢子粉的破壁率。
G、F 两液在喷射撞击后自由落体,在高压射流器B 的底部的漏斗形出料口b5 中流出进存储罐,无菌灌注为破壁灵芝孢子口服液,存储罐中的G、F 两混合液经过过滤、浓缩为高纯度多糖肽的破壁灵芝孢子粉。
最后声明
以上显示和描述了本工艺装置的主要特征及优点,本行业的技术人员应该了解,本设计的超高压发生器为单缸双作用隔腔式,由于灵芝孢子粉、口服液的食用卫生级要求高,今后本发明人雷鉴源将另行专利申请不再详述,蓄能器为二层不同材质热套,高压射流器、喷嘴、双向撞击靶为本装置的专用设计(附图2)不受上述实施例的限制,上述实施例和说明书中描述的只是说明本设计部分的结构原理,在不脱离本设计的精神和范围的前提下,本设计还会有各种变化和改进,这些变化和改进都应落入要求保护的本设计范围内,本设计要求保护的范围由所附的权利要求书及其等效物界。
Claims (1)
1.一种采用超高压射流破壁技术制备灵芝孢子粉口服液的工艺,其特征是:所述口服液由灵芝孢子粉80%、丰城草菇5%、蜂胶5%、富硒南烛5%、富硒紫薯5% 及纯净水30~45%,经超高压蓄能器、超音速射流撞击破壁、过滤浓缩制得,制备工艺中装置由超高压发生器、蓄能器、高压射流器、喷嘴、双向撞击靶、混凝器、空气压缩机、系统控制电脑主要部件组成,通过管路连接传感器、压力指示器附件;具体步骤如下:
(1)一是先将丰城草菇5% 用适量的纯净水浸泡后打浆过滤,再将5% 富硒南烛、5% 富硒紫薯清洗后加适量的纯净水打浆过滤,再把丰城草菇过滤汁与富硒南烛、富硒紫薯汁混合后备用,二是用适量的纯净水与蜂胶5%放在混凝器中溶解备用,再在30~45%的纯净水中加入灵芝孢子粉80%混合后为G液注入蓄能器,启动超高压发生器,由程序指示器打开管路控制阀,超高压发生器为蓄能器增压;
(2)将丰城草菇5%、富硒南烛5%、富硒紫薯5% 的过滤液与5%蜂胶溶解液一起混合后,进超高压容器以450Mpa超高压压力破壁、杀菌5min取出为H液备用;
(3)将G 液与H 液经混凝器充分混合后注入超高压反应釜,采用500Mpa压力稳压10 ~15min 释压后进入存储罐,在高压射流器两侧进料口的虹吸作用下液料从喷嘴中喷出,同轴线对向喷射在撞击靶上破壁。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410548543.7A CN104351761B (zh) | 2014-10-17 | 2014-10-17 | 一种超高压射流破壁灵芝孢子粉及口服液工艺装置 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410548543.7A CN104351761B (zh) | 2014-10-17 | 2014-10-17 | 一种超高压射流破壁灵芝孢子粉及口服液工艺装置 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104351761A CN104351761A (zh) | 2015-02-18 |
CN104351761B true CN104351761B (zh) | 2016-08-31 |
Family
ID=52519152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410548543.7A Expired - Fee Related CN104351761B (zh) | 2014-10-17 | 2014-10-17 | 一种超高压射流破壁灵芝孢子粉及口服液工艺装置 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104351761B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107227256A (zh) * | 2017-05-08 | 2017-10-03 | 浦江海璞食品科技有限公司 | 灵芝破壁装置 |
CN108041224A (zh) * | 2017-12-12 | 2018-05-18 | 桐城市放牛娃家庭农场有限公司 | 一种富硒孢子粉茶饮料及其制备方法 |
CN109053574A (zh) * | 2018-09-19 | 2018-12-21 | 湖南中茂生物科技有限公司 | 一种石杉碱甲的提取方法 |
CN108853151A (zh) * | 2018-09-19 | 2018-11-23 | 山东药乡生物工程有限公司 | 一种含孢子油灵芝孢子的破壁去壁方法 |
CN113522497B (zh) * | 2021-09-03 | 2023-03-17 | 湖南源科工程技术有限公司 | 一种用于植物孢子无氧化激光破壁生产线中的光能接收区 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101045071A (zh) * | 2007-04-25 | 2007-10-03 | 广州聚能生物科技有限公司 | 一种灵芝孢子的破壁方法 |
CN101380341A (zh) * | 2007-09-03 | 2009-03-11 | 刘柏钦 | 复方蜂胶制剂及其制备方法 |
CN102813199A (zh) * | 2012-09-03 | 2012-12-12 | 山东森健生物科技发展有限公司 | 一种预防及辅助治疗癌症、三高症及增强免疫力的保健食品 |
CN102973616A (zh) * | 2012-12-25 | 2013-03-20 | 江南大学 | 一种高生物活性灵芝孢子油及其超临界制备方法 |
CN103962007A (zh) * | 2014-05-06 | 2014-08-06 | 飞潮(无锡)过滤技术有限公司 | 一种自动程控超音速射流均质过滤器 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7357933B2 (en) * | 2004-05-05 | 2008-04-15 | Enhan Technology Holdings International Co., Ltd. | Sporoderm-broken germination-activated ganoderma lucidum spores for protection of dopaminergic neurons and treatment of Parkinson's disease |
-
2014
- 2014-10-17 CN CN201410548543.7A patent/CN104351761B/zh not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101045071A (zh) * | 2007-04-25 | 2007-10-03 | 广州聚能生物科技有限公司 | 一种灵芝孢子的破壁方法 |
CN101380341A (zh) * | 2007-09-03 | 2009-03-11 | 刘柏钦 | 复方蜂胶制剂及其制备方法 |
CN102813199A (zh) * | 2012-09-03 | 2012-12-12 | 山东森健生物科技发展有限公司 | 一种预防及辅助治疗癌症、三高症及增强免疫力的保健食品 |
CN102973616A (zh) * | 2012-12-25 | 2013-03-20 | 江南大学 | 一种高生物活性灵芝孢子油及其超临界制备方法 |
CN103962007A (zh) * | 2014-05-06 | 2014-08-06 | 飞潮(无锡)过滤技术有限公司 | 一种自动程控超音速射流均质过滤器 |
Also Published As
Publication number | Publication date |
---|---|
CN104351761A (zh) | 2015-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104351761B (zh) | 一种超高压射流破壁灵芝孢子粉及口服液工艺装置 | |
CN105249326A (zh) | 一种含有益生菌和中药提取物的发酵果蔬组合物及其制备方法 | |
CN102273639B (zh) | 燕窝香体制品及其制备方法 | |
CN1729874B (zh) | 一种桑叶桑椹菊花复合颗粒饮料的制备方法 | |
CN103555487B (zh) | 一种复方红葡萄酒的制造工艺 | |
CN105543052A (zh) | 一种养生补肾黄秋葵酒及其制备方法 | |
CN105454963B (zh) | 无添加食用糖和化学添加剂的全植物型饮料及其制备方法 | |
CN106333907A (zh) | 浴晶组合物及其制备方法 | |
CN103891962B (zh) | 一种美容瘦身的保健茶及其制备方法 | |
CN204090955U (zh) | 一种超高压射流破壁灵芝孢子粉及口服液工艺装置 | |
CN109907138A (zh) | 一种植物饮料及其制备方法 | |
CN104223297B (zh) | 一种延缓衰老的五味子保健口服液及其制备方法 | |
CN105707702A (zh) | 一种调理气血的燕麦片及其制备方法 | |
CN106165900A (zh) | 一种糖尿病患者特殊医学用途配方食品 | |
CN105010931A (zh) | 一种白梨血竭化痰生肌蜜及其制备方法 | |
CN106177433A (zh) | 一种包含青钱柳叶、葛根和玉竹的降血糖保健组合物 | |
CN106085879A (zh) | 一种用药材为培养基培养灵芝综合菌丝体 | |
CN106074707A (zh) | 全麻素在制备治疗胰腺炎的药物中的应用 | |
CN110251530A (zh) | 一种落叶松阿拉伯半乳聚糖组合物的制备方法及其临床应用 | |
CN109770133A (zh) | 野生蔓越莓保健饮品的制备方法 | |
CN110279052A (zh) | 一种提高免疫力的果蔬酵素饮料及其制备方法 | |
CN105456710B (zh) | 一种活血降脂药及其制备方法 | |
CN109043249A (zh) | 一种蓝莓l-阿拉伯糖复合饮料浓浆 | |
CN1299615C (zh) | 一种桑叶桑椹菊花复合颗粒饮料 | |
CN109463758B (zh) | 一种抗衰老及增加皮肤水分的复方产品及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160831 Termination date: 20181017 |
|
CF01 | Termination of patent right due to non-payment of annual fee |